<ѻýҕl>Safer Alternative to Cyclophosphamide at Hand for ILD?ѻýҕl> Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease Nov 14, 2022
<ѻýҕl>Novel BTK Inhibitor Looks Good for Sjogren's Syndromeѻýҕl> Phase II data show good efficacy by objective measures, even with strong placebo effect Nov 13, 2022
<ѻýҕl>ANCA-Associated Vasculitis: Novel Biologic Shows Promise for Replacing Steroidsѻýҕl> Small trial demonstrates big cut in steroid-linked adverse effects Nov 13, 2022
<ѻýҕl>Twelve-Month Data Back Pegloticase-Methotrexate Gout Comboѻýҕl> More support for add-on methotrexate to maintain protein drug's efficacy Nov 13, 2022
<ѻýҕl>Want a Few Weeks of Knee Pain Relief? Try Thisѻýҕl> Local nerve block proves mettle in randomized trial, though benefit didn't last long Nov 12, 2022
<ѻýҕl>For Systemic JIA, Start Biologics Earlyѻýҕl> Observational study shows excellent efficacy in systemic pediatric arthritis Nov 10, 2021
<ѻýҕl>Secukinumab: An Up-and-Coming Option in Giant Cell Arteritis?ѻýҕl> Phase II trial found sustained remission with steroid-sparing effects Nov 10, 2021
<ѻýҕl>Voclosporin Benefits in Nephritis Persist at 30 Monthsѻýҕl> No new safety signals seen in long-term extension for lupus nephritis Nov 09, 2021
<ѻýҕl>Vitamin D and Disease Prevention: Worth Another Look?ѻýҕl> Incidence of autoimmune disease decreased by 25-30% with dietary supplements Nov 08, 2021
<ѻýҕl>Guselkumab Response Durable in Psoriatic Arthritisѻýҕl> Skin and joint improvements persisted through 2 years of follow-up Nov 08, 2021
<ѻýҕl>Early Biologics Better in Juvenile Idiopathic Arthritisѻýҕl> After 2 years, more patients on combo biologic/DMARD regimen had inactive disease Nov 08, 2021
<ѻýҕl>Brepocitinib Shows Promise in Phase II Trial for PsAѻýҕl> Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations Nov 07, 2021
<ѻýҕl>Targeting IL-23 Succeeds in Psoriatic Arthritisѻýҕl> Patients had active, longstanding disease and inadequate responses to other agents Nov 07, 2021
<ѻýҕl>Can Abatacept Reverse Early Rheumatoid Arthritis?ѻýҕl> At-risk patients showed improvements in inflammation -- and also delays in disease onset Nov 06, 2021
<ѻýҕl>TYK2 Inhibition Promising in Psoriatic Arthritisѻýҕl> Phase II study found significant benefits for two doses of novel agent Nov 10, 2020
<ѻýҕl>High B-Cell Depletion Succeeds in Lupus Nephritisѻýҕl> Obinutuzumab was more effective at depleting B cells than rituximab Nov 08, 2020
<ѻýҕl>COVID Complications Common with Rheumatic Diseaseѻýҕl> Adverse outcomes included acute kidney injury and congestive heart failure Nov 08, 2020
<ѻýҕl>Rinvoq for RA: Benefits Persist Beyond 1 Yearѻýҕl> Manufacturer's extension study shows no loss of clinical response Nov 06, 2020
<ѻýҕl>ACR: Treat-to-Target Endorsed for Goutѻýҕl> Differs from ACP guideline for primary care: "they're wrong" Nov 15, 2019
<ѻýҕl>ACR: Draft OA Guidelines Stress Non-Drug Tx, Leave Opioid Door Openѻýҕl> But group comes down hard on stem cells, PRP, electrical therapy; downgrades hyaluronic acid shots Nov 14, 2019
<ѻýҕl>Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyѻýҕl> Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
<ѻýҕl>Reassurance on Live-Virus Shingles Vax With Anti-TNFsѻýҕl> Randomized trial indicates fears of infection unfounded Nov 11, 2019
<ѻýҕl>BTK Inhibitor Passes Phase II Test in RAѻýҕl> Novel mechanism for a rheumatoid arthritis drug Nov 11, 2019
<ѻýҕl>ACR: Can Tanezumab Be Revived for OA?ѻýҕl> Low incidence of rapidly progressive OA seen with lower doses Oct 26, 2018
<ѻýҕl>In Psoriatic Arthritis, Doubling Down on IL-17ѻýҕl> Bimekizumab targets both IL-17A and F; "astonishing" results in psoriatic arthritis Oct 25, 2018
<ѻýҕl>Treat-to-Target Strategy Cuts Mortality in Gout Patientsѻýҕl> Study sets serum urate therapeutic level Oct 24, 2018
<ѻýҕl>ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLEѻýҕl> Responses were sustained out to 1 year with ustekinumab Oct 24, 2018
<ѻýҕl>Childhood Trauma: Risk Factor for Lupus in Adulthood?ѻýҕl> Nurses Health Study data show a link Oct 24, 2018
<ѻýҕl>RA Guideline Adherence Spotty, Study Findsѻýҕl> Treat-to-target recommendation not followed for half of patients Oct 23, 2018
<ѻýҕl>Recurrent Post-Transplant Lupus Nephritis Decliningѻýҕl> Single-center study credits improvements in immunosuppression Oct 23, 2018
<ѻýҕl>Is JAK Inhibition the Next Big Thing in PsA?ѻýҕl> Proof-of-concept study suggests a potential role for oral filgotinib Oct 22, 2018
<ѻýҕl>New JAK1 Agent Beats Humira in Rheumatoid Arthritisѻýҕl> Thrombotic events balanced between upadacitinib, adalimumab, and placebo Oct 22, 2018
<ѻýҕl>Can Imaging Replace Biopsy for GCA Diagnosis?ѻýҕl> Ultrasound, PET/CT may offer advantages Oct 22, 2018
<ѻýҕl>Selective IL-23 Inhibitor Shines in Mid-Stage PsA Trialѻýҕl> Risankizumab broadly effective against joint and skin symptoms Nov 09, 2017
<ѻýҕl>PsA Structural Damage Inhibited with Secukinumabѻýҕl> Loading dose appears to improve outcomes, researchers say Nov 09, 2017
<ѻýҕl>Novel Drug Promising for IgG4-Related Diseaseѻýҕl> 8 of 15 patients achieved remission in phase II study Nov 08, 2017
<ѻýҕl>Prospects Good for Ustekinumab Gaining SLE Indicationѻýҕl> Positive phase II data reported in ACR late-breaker Nov 08, 2017
<ѻýҕl>ACR Poster Roundup: Novel OA Tx; Cancer and RA Biologicsѻýҕl> Selections from late-breaker poster presentations at rheumatology meeting Nov 08, 2017
<ѻýҕl>Mixed Results in Studies of Biosimilar-Originator Switchingѻýҕl> Is there a nocebo effect in changing between drugs supposed to be equal? Nov 08, 2017